Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.72 |
| ▸ | HTR2A | P28223 | 4/20 | 0.48 |
| ▸ | HTR6 | P50406 | 4/20 | 0.46 |
| ▸ | HTR7 | P34969 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32669276 | 0.87 | HTR1A (0.71) | HTR1AHTR2AHTR6HTR7GPR84 | |
| SCHEMBL25748559 | 0.85 | HTR1A (0.76) | HTR1AHTR2AHTR6HTR7HTR2C | |
| SCHEMBL25747526 | 0.84 | HTR1A (1.00) | HTR1AHTR2AHTR6HTR7MTNR1A | |
| SCHEMBL30916159 | 0.84 | HTR1A (1.00) | HTR1AHTR2AHTR6HTR7MTNR1A | |
| SCHEMBL32669230 | 0.84 | HTR1A (0.74) | HTR1AHTR2AHTR6HTR7HTR2C | |
| SCHEMBL25423705 | 0.81 | HTR1A (0.74) | HTR1AHTR2AHTR6HTR7GPR84 | |
| SCHEMBL25748550 | 0.81 | HTR1A (0.79) | HTR1AHTR2AHTR6HTR7MTNR1A | |
| SCHEMBL1196109 | 0.81 | HTR1A (0.75) | HTR1AHTR2AHTR6HTR7GPR84 | |
| SCHEMBL32669204 | 0.81 | HTR1A (0.70) | HTR1AHTR2AHTR6HTR7HTR2C | |
| SCHEMBL31390110 | 0.80 | HTR2A (0.73) | HTR1AHTR2AHTR6HTR7MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | HTR1A 4/4885HTR2A 12/4885HTR6 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.